FDA "disease" definition for supplements threatens structure/function claims -- CRN.
FDA "DISEASE" DEFINITION FOR SUPPLEMENT CLAIMS COULD "CONSUME" STRUCTURE/FUNCTION category, the Council for Responsible Nutrition says, rendering the classification of permissible dietary supplement statements "meaningless." In Aug. 11 comments to FDA, CRN urges the agency to withdraw the revised definition of "disease" set forth in its April 29 proposed rule delineating acceptable structure/function claims. CRN maintains it is "opposed to expansion of the disease definition, and in particular, to the inclusion of the phrase `structure or function' in the definition."
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.
Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.
Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.